ReviewFrontiers in microbiology2016
A Review of SHV Extended-Spectrum β-Lactamases: Neglected Yet Ubiquitous.
Review in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 4 syntheses or guidelines pooled it, 227 citations in OpenAlex.
- Pooled it
- Diversity, functional classification and genotyping of SHV β-lactamases inMicrobial genomics · 2024Pooled it
- A systematic review and meta-analysis on the prevalence of extended-spectrum beta-Lactamase-ProducingAfrican health sciences · 2024Pooled it
- The microbiome of bat guano: for what is this knowledge important?Applied microbiology and biotechnology · 2021Pooled it
- Extensively drug-resistant ESBL-producing enterobacterales and coexisting antimicrobial resistance genes are associated with mortality in critically ill patients with cancer.Scientific reports · 2026Article
- Article
- Dynamical-nonequilibrium alanine scanning for identifying allosteric positions in proteins.Biophysical journal · 2026Article
- PEPTiGEN: a tool for mining antimicrobial resistance PEPTides using GENe data of public available repositories.Bioinformatics (Oxford, England) · 2026Article
- Incidence of carbapenemase-resistant isolates ofNew microbes and new infections · 2026Article
- Occurrence of multidrug-resistant extended-spectrum β-lactamase (ESBL)-producingMicrobiology spectrum · 2026Article
- The Wildlife-Livestock Interface as a Bidirectional Pathway for the Spread of ESBL-ProducingAnimals : an open access journal from MDPI · 2026Review
- Short-Term Within-Host Genomic Diversity and Clone Turnover of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Exploration of novel β-lactamase inhibitors against Klebsiella pneumoniae using fragment-based drug discovery approach.Molecular diversity · 2026Article
- Partial purification and environmental application of CTX-type ESBL beta-lactamases from wastewater-derived E. coli isolates.BMC microbiology · 2026Article
- Exploring alterations in the gut resistome in medically treated inflammatory bowel disease patients.BMC microbiology · 2026Article
- Synergistic Potential of Repurposing non-β-lactam Compounds as Class A serine β-lactamases Inhibitor: Insights from MolecularDocking, Molecular Dynamics Simulations and Antimicrobial Potentiation.Scientific reports · 2026Article
- Poultry Proteus mirabilis in selected areas of Hunan, China: Resistance profiles and virulence genes.Poultry science · 2026Article
- The mecillinam resistome inAntimicrobial agents and chemotherapy · 2026Article
- Molecular surveillance of foodborne bacterial pathogens and resistome in food products from Hong Kong.Microbiology (Reading, England) · 2026Article
- Wildlife as sentinel of antimicrobial resistance inFrontiers in microbiology · 2026Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-lactamases are the primary cause of resistance to β-lactams among members of the family Enterobacteriaceae. SHV enzymes have emerged in Enterobacteriaceae causing infections in health care in the last decades of the Twentieth century, and they are now observed in isolates in different epidemiological settings both in human, animal and the environment. Likely originated from a chromosomal penicillinase of Klebsiella pneumoniae, SHV β-lactamases currently encompass a large number of allelic variants including extended-spectrum β-lactamases (ESBL), non-ESBL and several not classified variants. SHV enzymes have evolved from a narrow- to an extended-spectrum of hydrolyzing activity, including monobactams and carbapenems, as a result of amino acid changes that altered the configuration around the active site of the β -lactamases. SHV-ESBLs are usually encoded by self-transmissible plasmids that frequently carry resistance genes to other drug classes and have become widespread throughout the world in several Enterobacteriaceae, emphasizing their clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.